KRAS and hepatocellular carcinoma: In accordance with the finding that inhibition of PDE6D impairs the enrichment of RAS proteins at the plasma membrane [17,21], we found that PDE6D suppression (using si-RNA technique and pharmacologic inhibition of the PDE6D-KRAS interaction) reduced MAPK-ERK activation in HCC cells (Figure S1A,B).